Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Filings
41 filings of ALKEM since November 2024; the newest 40 below.
board outcome 11, presentation 11, transcript 8, dividend 5, results 4, scheme 2
| Filed | Type | Subject | |
|---|---|---|---|
| 12 Nov 2026 | presentation Acquisition, Capex, Management change, Results | Alkem Laboratories Limited has informed the Exchange about Investor PresentationAI summaryAlkem Laboratories filed its press release and analyst presentation on Q2 and H1 FY27 results (quarter ended September 30, 2026), dated November 12, 2026. Total revenue from operations was ₹45,520 million, up 13.8% YoY; India sales were ₹30,275 million (up 9.5% YoY) and International sales were ₹14,540 million (up 22.3% YoY). EBITDA was ₹10,252 million, an EBITDA margin of 22.5%; net profit after non-controlling interest was ₹6,753 million, down 11.7% YoY. Management (MD Sandeep Singh) said the India business showed continued momentum and the international business made steady progress despite US pricing pressure; the company also welcomed Dr. Amrut Naik as Chief Executive Officer. Net cash stood at ₹49,054 million as on September 30, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Nov 2026 | board outcome Results | Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryAlkem Laboratories' board approved the standalone and consolidated unaudited financial results for the quarter and half year ended 30 September 2026 at its meeting on 12 November 2026. The board meeting ran from 11:30 a.m. to 1:40 p.m., and the results and the statutory auditor's limited review report (Deloitte Haskins & Sells LLP) were enclosed. The auditor's review report states nothing came to its attention that the consolidated results have not been prepared per Ind AS 34 or contain a material misstatement. The filing does not state the revenue, profit or other figures of the company's own results; the auditor's report gives figures only for certain subsidiaries. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 Aug 2026 | transcript Acquisition, Capex, Guidance, Legal, Results | Alkem Laboratories Limited has informed the Exchange about Q1 FY2027 - Earnings Conference Call TranscriptAI summaryAlkem Laboratories filed the transcript of its Q1 FY2027 earnings conference call, held on 14 August 2026. Management said revenue from operations was INR3,740 crores, up close to 11% year-on-year; India sales were INR2,497 crores (up 10.3%) and international sales were INR1,222 crores (up 16%). Management said EBITDA margin was 20.5% and net profit fell 21.7%, which it attributed to taxation reasons. Management said the company grew 13.2% in the Indian pharmaceutical market (IPM), versus 12.2% for the market per IQVIA data, and that its Daman facility received an OAI status, with U.S. supplies continuing without interruption. Management said the U.S. CDMO operation incurs about INR60 crores of quarterly operating expense and needs roughly USD25-30 million of annualised revenue to break even, and that Occlutech acquisition was completed in mid-July 2026 with a target of about INR400 crores of sales for the rest of the year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2026 | presentation Legal, Results | Alkem Laboratories Limited has informed the Exchange about Investor PresentationAI summaryAlkem Laboratories filed its press release and analyst presentation on Q1FY27 results (quarter ended June 30, 2026). Total revenue from operations was ₹37,402 million, up 10.9% YoY; India sales ₹24,978 million (up 10.3%) and international sales ₹12,223 million (up 16.0%). EBITDA was ₹7,661 million, a 20.5% margin, up 3.7% YoY; net profit after non-controlling interest was ₹5,200 million, down 21.7% YoY. Management (MD Sandeep Singh) said the company started FY27 on a steady note, but that areas need improvement, particularly execution, operational and regulatory priorities, and consistency of performance. The Daman (India) formulations facility had an OAI (Official Action Indicated) status in August 2026 after an April 2026 inspection. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2026 | board outcome Results | Alkem Laboratories Limited has submitted to the Exchange, outcome of the Board Meeting held on 14th August, 2026AI summaryAlkem Laboratories' board approved the standalone and consolidated unaudited financial results for the quarter ended 30 June 2026 at a meeting held on 14 August 2026 (11.00 a.m. to 1.40 p.m.). The Statutory Auditors (Deloitte Haskins & Sells LLP) issued a limited review report on the consolidated results with an unmodified conclusion. Auditors did not review four subsidiaries with total revenue of Rs. 2,945.1 million, net profit after tax of Rs. 47.8 million and total comprehensive income of Rs. 66.2 million for the quarter. Auditors also noted twenty subsidiaries not reviewed by their auditors, with total revenue of Rs. 2,261.9 million, net loss after tax of Rs. 100.6 million and total comprehensive income of Rs. (82.7) million; management considers these not material. The filing does not state the headline revenue or profit figures for the group. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 01 Jun 2026 | transcript Acquisition, Dividend / buy-back, Guidance, Legal, Management change, Results | Alkem Laboratories Limited has informed the Exchange about TranscriptAI summaryAlkem Laboratories filed the transcript of its Q4 FY2026 earnings conference call held on 28 May 2026. Management said FY26 EBITDA crossed INR3,000 crores; Q4 total revenue from operations was INR36,033 million (up 14.6% Y-o-Y) and FY26 revenue was INR1,47,123 million (up 13.5%). Management guided that the tax rate will be around 27% to 29% from FY27 under the new tax regime, and that dividend payout of 25% to 30% of PAT will continue, with no major reduction in absolute dividend value. Management said it does not foresee further acquisitions for at least the next 12 months, and that US Denosumab biosimilar approval is expected around Q1 of next year, with no launch this year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 May 2026 | presentation Guidance, Legal, Results | Alkem Laboratories Limited has informed the Exchange about Investor PresentationAI summaryAlkem Laboratories filed its press release and analyst presentation on Q4FY26 and FY26 results, dated May 28, 2026. Q4FY26 total revenue from operations was ₹36,033 million, up 14.6% YoY; EBITDA was ₹5,174 million (14.4% margin vs 12.4% in Q4FY25); net profit after non-controlling interest was ₹2,365 million, down 22.7% YoY. FY26 total revenue from operations was ₹147,123 million, up 13.5% YoY; EBITDA was ₹30,052 million (20.4% margin vs 19.4% in FY25); net profit after non-controlling interest was ₹23,018 million, up 6.3% YoY. Management (CEO Dr. Vikas Gupta) said FY26 recorded the highest ever EBITDA and that the company enters FY27 on a firm foundation, expecting healthy growth supported by chronic therapies and an international launch pipeline. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 May 2026 | dividend Dividend / buy-back, Management change, Results | Alkem Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 28, 2026, recommended Final Dividend of Rs. 10 per equity share.AI summaryBoard of Alkem Laboratories approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, and the auditors gave unmodified opinions. The Board recommended a final dividend of Rs. 10 per equity share (face value Rs. 2) for FY2025-26, subject to shareholder approval at the AGM. The 52nd AGM is fixed for 27 August 2026, with the cut-off date for the AGM on 20 August 2026. The dividend record date is 7 August 2026, and the dividend, if declared, will be paid from 1 September 2026. The Board approved re-appointment of Mrs. Madhurima Singh as Executive Director for five years from 20 December 2026 to 19 December 2031, subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 May 2026 | board outcome Dividend / buy-back, Management change, Results | Alkem Laboratories Limited has submitted to the Exchange, Outcome of the Board Meeting held on 28th May, 2026AI summaryAlkem Laboratories' board, at its meeting on 28 May 2026, approved the standalone and consolidated audited financial results for the quarter and year ended 31 March 2026, with unmodified audit opinions. The board recommended a final dividend of Rs. 10 per equity share (face value Rs. 2) for FY2026, subject to shareholder approval at the AGM. The 52nd AGM is fixed for 27 August 2026; the AGM cut-off date is 20 August 2026 and the dividend record date is 7 August 2026, with payment from 1 September 2026 if approved. The board approved the re-appointment of Mrs. Madhurima Singh as Executive Director for five years from 20 December 2026 to 19 December 2031, subject to shareholder approval at the AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Apr 2026 | results Results | The Exchange had sought clarification from Alkem Laboratories Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the ComAI summaryAlkem Laboratories responded to an NSE clarification dated 26 June 2025 about its XBRL submission of financial results for the quarter ended 31 March 2025. The NSE had flagged that the XBRL filing wrongly described the quarter-ended results as audited. The company has submitted revised standalone and consolidated XBRL files for the quarter ended 31 March 2025 and asked NSE to record them. The letter is dated 1 July 2025, although the filing date is shown as 10 April 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Feb 2026 | presentation Capex, Guidance, Legal | Alkem Laboratories Limited has informed the Exchange about Investor PresentationAI summaryAlkem Laboratories filed an updated investor meet presentation on Alkem MedTech's strategic way forward, for a meet held on 18 February 2026 at 4:30 p.m. The presentation cites a global MedTech market of $680 billion, projected to reach $870 billion by 2030, and an Indian MedTech market of $16 billion in 2025, projected at $30 billion by 2030 (BCG CII Aug 2025 report). It identifies musculoskeletal, cardiovascular, and IVD & wound care as priority segments. On musculoskeletal, management states knee and hip products are in approval process: CE approval for knee and hip with expected timelines of Q4 FY28, and CIS country approval for knee and hip with expected timelines of Q1 FY28. Management states the planned launches are knee in Q2 FY27 and hip in Q4 FY27, with 150+ repeat customers and a 5-year vision of 250K+ implants and 10% market share in India's large joints market. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 Feb 2026 | presentation Acquisition, Capex, Guidance, Legal | Alkem Laboratories Limited has informed the Exchange about Investor PresentationAI summaryAlkem Laboratories filed an investor meet presentation on Alkem MedTech's strategic way forward, to be held on February 18, 2026 at 4:30 p.m. The presentation covers a global MedTech market of $680Bn (2025), projected to reach $870Bn by 2030, and an India market of $16Bn (2025) projected to reach $30Bn by 2030 (about 13% p.a.). Alkem MedTech has identified musculoskeletal and cardiovascular as priority segments; the musculoskeletal plan lists CE approval for Knee and Hip as expected in Q4 FY28 and CIS country approval for Knee and Hip as expected in Q1 FY28. Management's stated plan for cardiovascular includes acquisition of an established global cardio asset portfolio, expansion via an established platform, and cost optimization. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 Feb 2026 | transcript Acquisition, Capex, Guidance, Results | Alkem Laboratories Limited has informed the Exchange about TranscriptAI summaryAlkem Laboratories filed the transcript of its Q3 FY26 earnings conference call, held on 13 February 2026. Management reported Q3 FY26 total revenue of INR37,368 million (up 10.7% YoY), international sales of INR12,157 million (up 26.6%), India sales of INR24,959 million (up 5.5%), EBITDA of INR8,280 million (9% YoY growth, 22.2% margin) and net profit of INR6,360 million (up 1.6%), with an exceptional item of INR528 million related to the Labour Codes. Management said it is on track to deliver full-year guidance and that domestic business grew close to 10% YTD, with double-digit growth in Q3 after adjusting for a high base from Q3 FY25. Management announced a major acquisition of a 55% stake in Occlutech, a cardiology medtech company, with an initial investment of about INR1,100 crore and a further INR100-200 crore over two years for R&D; it targets 10% EBITDA by FY27 for that company. Managing Director Sandeep Singh said Alkem MedTech could reach revenue of about INR1,000 crore in 3-5 years, with incremental medtech investment of INR200-300 crore over 3-4 years. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | presentation Acquisition, Guidance, Results | Alkem Laboratories Limited has informed the Exchange about Investor PresentationAI summaryAlkem Laboratories filed its press release and analyst presentation on Q3 and 9MFY26 results, dated 13 February 2026. Q3 FY26 total revenue from operations was ₹37,368 million, up 10.7% YoY; India sales were ₹24,959 million (up 5.5%) and international sales were ₹12,157 million (up 26.6%). EBITDA was ₹8,280 million, a margin of 22.2% vs 22.5% in Q3 FY25; net profit after non-controlling interest was ₹6,360 million, up 1.6% YoY. The Q3 exceptional item includes ₹528 million on a preliminary basis related to the Government of India's notification of the four Labour Codes. The company also announced a binding term sheet to acquire a majority stake in Occlutech Holding AG, a Swiss medical devices company, through its subsidiary Alkem MedTech Pvt Ltd. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | scheme Acquisition, Legal | Alkem Laboratories Limited has informed the Exchange about Amalgamation/MergerAI summaryAlkem Laboratories' board approved on 13 February 2026 the amalgamation of its wholly-owned subsidiary Adroit Biomed Limited (transferor) into the company (transferee) by a scheme under Sections 230-232 of the Companies Act, 2013. The scheme is subject to sanction by the Mumbai bench of the NCLT and to shareholder and/or creditor approvals if directed by the NCLT, plus other applicable approvals. Financials as on March 31, 2025: Adroit Biomed net worth INR 75.7 Mn and total revenue from operations INR 596.8 Mn; Alkem net worth INR 1,23,218.3 Mn and total revenue from operations INR 88,134.4 Mn. Management's stated rationale includes consolidating similar pharmaceutical trading businesses, reducing overheads, and simplifying the group structure. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | dividend Dividend / buy-back, Results | Alkem Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on February 13, 2026, declared Interim Dividend of Rs. 43 per equity share.AI summaryAlkem Laboratories' board meeting held on 13 February 2026 approved standalone and consolidated unaudited financial results for the quarter and nine months ended 31 December 2025, with the statutory auditor's limited review report enclosed. The board declared an interim dividend of Rs. 43 per equity share (face value Rs. 2) for financial year 2025-2026. The record date for the interim dividend is Friday, 20 February 2026, and payment will be made on and from 6 March 2026. The board meeting commenced at 11:00 a.m. and concluded at 1:45 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | board outcome Dividend / buy-back, Results | Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryAlkem Laboratories' board meeting held on 13 February 2026 approved the standalone and consolidated unaudited financial results for the quarter and nine months ended 31 December 2025, with the auditor's limited review report enclosed. The board declared an interim dividend of Rs. 43 per equity share (face value Rs. 2 per share) for financial year 2025-2026. The record date for the interim dividend is Friday, 20 February 2026, and payment will be made on and from 6 March 2026. The board meeting ran from 11:00 a.m. to 1:45 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | dividend Dividend / buy-back, Results | Alkem Laboratories Limited has informed the Exchange about Outcome of Board Meeting held on 13th February, 2026AI summaryAlkem Laboratories filed the outcome of its board meeting held on 13 February 2026, which approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with the auditor's limited review report enclosed. The board declared an interim dividend of Rs. 43 per equity share (face value Rs. 2) for financial year 2025-2026. The record date for the interim dividend is Friday, 20 February 2026, and payment will be made on and from 6 March 2026. The meeting commenced at 11:00 a.m. and concluded at 1:45 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Feb 2026 | scheme Acquisition, Legal | Alkem Laboratories Limited has informed the Exchange about Amalgamation/MergerAI summaryAlkem Laboratories' board approved, on 6 February 2026, the amalgamation of Alkem Medtech Ortho Private Limited (wholly owned subsidiary of Alkem Medtech Private Limited) into Alkem Medtech Private Limited via a scheme under Sections 230-232 of the Companies Act, 2013, subject to NCLT Mumbai and Ahmedabad bench sanction. Per the filing (financials as on 31 March 2025), the transferor company had paid-up equity share capital of Rs 3,50,00,000 and net worth of negative Rs 12,12,47,226; total income Rs 68,17,230. The transferee company had paid-up equity share capital of Rs 3,80,37,51,800, net worth of Rs 448,10,94,758 and total income of Rs 8,80,59,457. The companies are wholly owned subsidiaries within the group; no share exchange ratio or consideration applies, as the transferor's shares held by the transferee will be cancelled, and no change in the listed company's shareholding pattern is expected. Neither company's equity shares are listed on any stock exchange. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Nov 2025 | transcript Capex, Guidance, Legal, Results | Alkem Laboratories Limited has informed the Exchange about TranscriptAI summaryAlkem Laboratories filed the transcript of its Q2 & H1 FY26 earnings conference call, held on 13 November 2025. Management said Q2 FY26 revenue from operations was a record INR40,010 million, up 17.2% Y-o-Y; India sales INR27,660 million (up 12.4%); U.S. sales INR7,649 million (up 28%); non-U.S. sales INR4,241 million (up 32.4%). EBITDA rose 22.3% Y-o-Y to INR9,208 million (23% margin); net profit after minority interest was INR7,651 million (up 11.1%). CEO Vikas Gupta said the company expects full-year FY26 EBITDA margin of 19.5% to 20%, with about INR100 crore of U.S. CDMO plant opex in H2 and a GST-related impact of INR50-60 crore on H2 from the Sikkim facility benefit. Management guided India growth to outperform the market by 100-150 basis points, non-U.S. growth in the high teens to around 20%, and R&D at 4% to 5% of revenue. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Nov 2025 | presentation Results | Alkem Laboratories Limited has informed the Exchange about Investor PresentationAI summaryAlkem Laboratories filed its press release and analyst presentation on Q2 and H1 FY26 results, dated 13 November 2025. Q2 FY26 total revenue from operations was ₹40,010 million, up 17.2% YoY; India sales were ₹27,660 million (up 12.4%) and international sales were ₹11,890 million (up 29.5%). EBITDA was ₹9,208 million, a 23.0% margin, up 22.3% YoY; profit after minority interest was ₹7,651 million, up 11.1% YoY. R&D spend was ₹1,302 million, or 3.3% of revenue from operations, versus 4.3% in Q2 FY25. CEO Dr. Vikas Gupta said Q2 FY26 was "another strong quarter" with robust growth across India, the US and key international markets, and that the company remains focused on accelerating growth. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Nov 2025 | board outcome Results | Alkem Laboratories Limited has informed the Exchange regarding Board meeting held on November 13, 2025.AI summaryAlkem Laboratories filed the outcome of its board meeting held on 13 November 2025. The board approved the standalone and consolidated unaudited financial results for the quarter and half year ended 30 September 2025, with the Statutory Auditors' limited review report enclosed. The board meeting ran from 11:40 a.m. to 1:30 p.m. The filing does not state the revenue or profit figures, and it contains no management commentary or outlook. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Nov 2025 | board outcome Results | Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryAlkem Laboratories filed the outcome of its board meeting held on 13 November 2025. The board approved the standalone and consolidated unaudited financial results for the quarter and half year ended 30 September 2025, with the Statutory Auditors' limited review report (Deloitte Haskins & Sells LLP) enclosed. The board meeting ran from 11.40 a.m. to 1.30 p.m. The filing does not state the revenue or profit figures, and it contains no dividend or outlook information. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Aug 2025 | transcript Guidance, Results | Alkem Laboratories Limited has informed the Exchange about Transcript of "Q1 FY2026 Earnings conference call" hosted by the Company on Tuesday, 12th August, 2025.AI summaryAlkem Laboratories filed the transcript of its Q1 FY2026 earnings conference call, held on 12 August 2025. Management reported Q1 FY26 total revenue from operations of INR33,711 million, up 11.2% Y-o-Y, and EBITDA of INR7,391 million, up 21.4%, at a margin of 21.9%. Net profit after minority interest was INR6,643 million, up 21.8% Y-o-Y; India sales were INR22,656 million, up 12%. CEO Dr. Vikas Gupta said the company will stay with its FY26 guidance, as it is too early to revise after one quarter, and that the probability of meeting it is much higher given the strong start. Management said the Alkem MedTech business had Q1 revenue of about INR2.5 crore and expects around INR20 crore for FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Aug 2025 | presentation Results | Alkem Laboratories Limited has informed the Exchange about Investor PresentationAI summaryAlkem Laboratories filed its press release and analyst presentation on Q1 FY26 results (quarter ended June 30, 2025) and a notice of its earnings conference call. Total revenue from operations was ₹33,711 million, up 11.2% YoY; India sales were ₹22,650 million (up 12.0%) and international sales were ₹10,539 million (up 8.9%). EBITDA was ₹7,391 million, a 21.9% margin vs 20.1% in Q1 FY25, with EBITDA up 21.4% YoY; net profit after minority interest was ₹6,643 million, up 21.8% YoY. Management (CEO Dr. Vikas Gupta) said Q1 FY26 "marked a strong start to the year, with healthy growth across both our domestic and international markets," driven by topline growth and an improved gross margin, and said the company is accelerating its focus on the non-US business segment. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Aug 2025 | board outcome Results | Alkem Laboratories Limited has informed the Exchange regarding Board meeting held on August 12, 2025.AI summaryAlkem Laboratories' board approved the standalone and consolidated unaudited financial results for the quarter ended 30 June 2025 at a meeting on 12 August 2025. The board meeting ran from 11.00 a.m. to 1.25 p.m. on 12 August 2025. The filing encloses the financial results and the statutory auditor's (Deloitte Haskins & Sells LLP) limited review report, which states nothing has come to its attention that the statement has material misstatement. The auditor did not review five subsidiaries with total revenue of Rs. 3,548.2 million for the quarter, and 21 subsidiaries with total revenue of Rs. 2,156.9 million were reviewed by management only. The numbers for revenue, profit and EPS are in the enclosed results, which the filing pages do not show. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Aug 2025 | board outcome Results | Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryAlkem Laboratories' board approved the standalone and consolidated unaudited financial results for the quarter ended 30 June 2025 at a meeting held on 12 August 2025. The board meeting commenced at 11.00 a.m. and concluded at 1.25 p.m. The statutory auditor, Deloitte Haskins & Sells LLP, issued a limited review report with an unmodified conclusion. The filing does not state revenue, profit or other figures in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Jun 2025 | results | The Exchange has sought clarification from Alkem Laboratories Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Com | |
| 02 Jun 2025 | transcript Capex, Guidance, Results | Alkem Laboratories Limited has informed the Exchange about TranscriptAI summaryAlkem Laboratories filed the transcript of its Q4 FY2025 earnings conference call held on 29 May 2025. Management reported Q4 FY25 revenue from operations of Rs 31,438 million (up 7.1% YoY), India sales of Rs 21,355 million (up 8.1%), international sales of Rs 9,747 million (up 7.2%) and net profit of Rs 3,059 million (up 4.2%). For FY25, revenue from operations was Rs 1,29,645 million (up 2.3%), EBITDA Rs 25,122 million (up 11.9%, margin 19.4% vs 17.7%) and net profit Rs 21,655 million (up 20.6%). Management guided FY26 EBITDA margin stable at about 19.5% and US business growth in the mid-single digits; domestic growth at least 100 basis points above the market. The biosimilar CDMO plant is on track to be operational by Q2 FY26, with cumulative capex of about Rs 550 crore, of which Rs 450 crore was spent in FY25. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2025 | presentation Results | Alkem Laboratories Limited has informed the Exchange about Investor PresentationAI summaryAlkem Laboratories filed its press release and analyst presentation on Q4FY25 and FY25 results, dated May 29, 2025. Q4FY25 total revenue from operations was ₹31,438 million, up 7.1% YoY; EBITDA was ₹3,913 million, with an EBITDA margin of 12.4% vs. 13.7% in Q4FY24; net profit (after minority interest) was ₹3,059 million, up 4.2% YoY. FY25 total revenue from operations was ₹129,645 million, up 2.3% YoY; EBITDA was ₹25,122 million, with an EBITDA margin of 19.4% vs. 17.7% in FY24; net profit (after minority interest) was ₹21,655 million, up 20.6% YoY. Management (CEO Dr. Vikas Gupta) said the company ended the year on a good note with healthy India growth in Q4 and improved full-year profitability and margins, and that it is seeing good traction in international markets excluding the Americas. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2025 | dividend Dividend / buy-back, Management change, Results | Alkem Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2025, recommended Final Dividend of 8 per equity share.AI summaryBoard of Alkem Laboratories approved the standalone and consolidated audited results for the quarter and year ended 31 March 2025. The Board recommended a final dividend of Rs. 8 per equity share of Rs. 2 each for FY 2024-25, subject to shareholder approval at the AGM. The AGM is to be held on 25 August 2025, with a cut-off date of 18 August 2025 and a dividend record date of 8 August 2025; the dividend, if declared, will be paid from 29 August 2025. The Board appointed Mr. Ranjal Laxmana Shenoy and Ms. Neela Bhattacherjee as Independent Directors for five years from 13 July 2025 to 12 July 2030, subject to shareholder approval. The Board appointed Manish Ghia & Associates as Secretarial Auditors for five years, from FY 2025-26 to FY 2029-30, subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2025 | board outcome Dividend / buy-back, Legal, Management change, Results | Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.AI summaryAlkem Laboratories' board, at its meeting on 29 May 2025, approved the standalone and consolidated audited financial results for the quarter and year ended 31 March 2025, with unmodified audit opinions. The board recommended a final dividend of Rs 8 per equity share of Rs 2 each for FY2024-25, subject to shareholder approval at the AGM on 25 August 2025. Record date for the final dividend is 8 August 2025, with payment on and from 29 August 2025; AGM cut-off date is 18 August 2025. Ranjal Laxmana Shenoy and Neela Bhattacherjee were appointed as Additional Independent Directors for five years from 13 July 2025 to 12 July 2030, subject to shareholder approval. Manish Ghia & Associates was appointed as Secretarial Auditors for five years from 1 April 2025 to 31 March 2030, subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2025 | board outcome Dividend / buy-back, Management change, Results | Alkem Laboratories Limited has informed the Exchange regarding Board meeting held on May 29, 2025.AI summaryAlkem Laboratories filed the outcome of its board meeting held on 29 May 2025, which approved audited standalone and consolidated results for the quarter and year ended 31 March 2025. The board recommended a final dividend of Rs 8 per equity share (face value Rs 2) for FY2025, subject to shareholder approval at the AGM on 25 August 2025. Record date for the final dividend is 08 August 2025, with payment on and from 29 August 2025; AGM cut-off date is 18 August 2025. The board approved appointing Mr. Ranjal Laxmana Shenoy and Ms. Neela Bhattacherjee as Independent Directors for five years from 13 July 2025 to 12 July 2030, subject to shareholder approval. The board approved appointing Manish Ghia & Associates as Secretarial Auditors for five years (FY2025-26 to FY2029-30), subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Mar 2025 | presentation Guidance | Alkem Laboratories Limited has informed the Exchange about Investor PresentationAI summaryAlkem Laboratories filed an investor presentation for its analyst/institutional investor meetings at the HSBC Global Investment Summit 2025 in Hong Kong on 24 and 25 March 2025. The presentation states revenue from global operations of INR 125+ Bn in FY24, with about 70% of revenue from India, and market capitalisation of INR 555+ Bn as of February 2025. It shows revenue growth from INR 11,842 Mn in FY09 to INR 124,392 Mn in FY24, a CAGR of about 17% for FY10-24 (revenue includes Enzene). Management states three growth pillars: international business scaling to 40+ Bn, TGx scaling up to 17+ Bn, and growth in the chronic portfolio. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Feb 2025 | transcript Acquisition, Guidance, Results | Alkem Laboratories Limited has informed the Exchange about TranscriptAI summaryAlkem Laboratories filed the transcript of its Q3 FY2025 earnings conference call, held on 7 February 2025. Management reported Q3 revenue from operations of INR 33,743 million (up 1.5% Y-o-Y) and 9M revenue of INR 98,208 million (up 0.9%); Q3 EBITDA of INR 7,594 million at a 22.5% margin; Q3 net profit of INR 6,258 million (up 5.2%). Management said it was on track with its FY25 EBITDA margin guidance of around 19% and announced two acquisitions: Adroit (cash consideration INR 140 crore) and Bombay Ortho (cash consideration INR 147 crore). Management expects India growth to be broadly in line with the market (about 7%) for the year and sees US price erosion at mid-single digits next year, offset by launches and volume growth. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Feb 2025 | results Results | Attached herewith is the Integrated filing (financials) for QE 31.12.2024AI summaryAlkem Laboratories filed its integrated filing (financial) with the exchanges, enclosing the unaudited consolidated financial results for the quarter and nine months ended 31 December 2024, reviewed by Deloitte Haskins & Sells LLP with an unmodified review conclusion. The filing states that the statutory auditor's review report covers the consolidated results, with five subsidiaries reviewed by other auditors (quarter total revenue Rs 4,141.0 million; nine-month revenue Rs 12,111.7 million). Nineteen subsidiaries were not reviewed by their auditors; per management, these are not material to the group (quarter revenue Rs 1,817.5 million; nine-month revenue Rs 5,420.7 million). The company also stated that the statement on deviation or variation of proceeds and the statement on outstanding default on loans and debt securities are not applicable. The actual headline profit and loss figures are in an annexure not included in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Feb 2025 | presentation Results | Alkem Laboratories Limited has informed the Exchange about Investor PresentationAI summaryAlkem Laboratories filed its press release and analyst presentation on Q3 and 9MFY25 results (quarter and nine months ended December 31, 2024). Q3FY25 total revenue from operations was ₹33,743 million (YoY growth 1.5%); EBITDA was ₹7,594 million with a 22.5% margin (vs 21.3% in Q3FY24); net profit after minority interest was ₹6,258 million (YoY growth 5.2%). 9MFY25 total revenue from operations was ₹98,208 million (YoY growth 0.9%); EBITDA was ₹21,208 million with a 21.6% margin (vs 18.9% in 9MFY24); net profit after minority interest was ₹18,596 million (YoY growth 23.8%). CEO Dr Vikas Gupta said actions taken to improve profitability continue to deliver positive results and that the company is confident these initiatives will drive sustainable growth. A conference call on the results was scheduled for February 7, 2025 at 4:00 pm IST. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Feb 2025 | results Dividend / buy-back, Results | Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summaryAlkem Laboratories reported unaudited standalone and consolidated results for the quarter and nine months ended 31 December 2024 (Q3FY25 / 9MFY25). Q3FY25 total revenue from operations was Rs 33,743 million (up 1.5% YoY); EBITDA was Rs 7,594 million with a 22.5% margin (vs 21.3%); net profit after minority interest was Rs 6,258 million (up 5.2% YoY). 9MFY25 total revenue from operations was Rs 98,208 million (up 0.9% YoY); EBITDA was Rs 21,208 million with a 21.6% margin; net profit after minority interest was Rs 18,596 million (up 23.8% YoY). The Board declared an interim dividend of Rs 37 per equity share (face value Rs 2) for FY2024-25, with record date 14 February 2025 and payment from 28 February 2025. CEO Dr Vikas Gupta said actions taken to improve profitability continue to deliver positive results and he is confident these initiatives will drive sustainable growth. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Feb 2025 | dividend Dividend / buy-back, Results | Alkem Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on February 07, 2025, declared Interim Dividend of 37 per equity share.AI summaryBoard of Alkem Laboratories approved standalone and consolidated unaudited financial results for the quarter and nine months ended 31 December 2024 (results enclosed with the filing). Board declared an interim dividend of Rs. 37 per equity share (face value Rs. 2 per share) for financial year 2024-2025. Record date for the interim dividend is Friday, 14 February 2025. Payment date for the interim dividend is 28 February 2025. Board meeting was held on 7 February 2025, from 11:00 a.m. to 1:40 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Feb 2025 | board outcome Dividend / buy-back, Results | Alkem Laboratories Limited has informed the Exchange regarding Board meeting held on February 07, 2025.AI summaryBoard meeting held on 07 February 2025 approved the standalone and consolidated unaudited financial results for the quarter and nine months ended 31 December 2024, enclosed with the limited review report. Board declared an interim dividend of Rs. 37 per equity share (face value Rs. 2 per share) for financial year 2024-2025. Record date for the interim dividend is Friday, 14 February 2025, and payment will be made on and from 28 February 2025. The board meeting commenced at 11:00 a.m. and concluded at 1:40 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.